Background:Studies have shown that,Shengmai injection(Shengmai decoction)which has been included in the diagnosis and treatment of coronavirus disease 2019(COVID-19),is effective in the early treatment of patients wit...Background:Studies have shown that,Shengmai injection(Shengmai decoction)which has been included in the diagnosis and treatment of coronavirus disease 2019(COVID-19),is effective in the early treatment of patients with severe COVID-19.However,the mechanism of its intervention in severe stage of COVID-19 at molecular level is still unclear.Therefore,it is necessary to further explore the mechanism of Shengmai decoction in the treatment of patients with severe COVID-19 based on network pharmacology.Methods:The Traditional Chinese Medicine Systems Pharmacology,BATMAN,UniProt databases and the published literatures which contain the reported compounds that have therapeutic effects on COVID-19 were used to screen out the active ingredients and targets of Shengmai decoction,and the“drug-active compound-target”network was constructed.The GeneCards database was used to screen out the targets of COVID-19.The protein-protein interaction network map was constructed by mapping two genes,and the network of active ingredients,targets and disease was constructed using Cytoscape software.Thereafter,Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of the key targets were performed using the Metascape Site Maintenance website and David databases.The Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes pathway enrichment of the mapping targets were analyzed.Results:The active component-target network contained 73 main compounds and 457 targets.The first five main active components(hydroquinone,guanosine,ophiopogon C,ophiopogon B,ophiopogon D)were obtained by topological analysis of 33 common targets.Using the Matthews correlation coefficient algorithm,the key targets included albumin,tumor necrosis factor,and cyclic adenosine response element binding.Compounds in Shengmai decoction were found to have good binding effect and strong interaction with caspase-8,caspase-3,apoptosis regulator Bcl-2,tumor necrosis factor,C-C motif chemokine 3,to inhibit the inflammatory response and improve lung injury.Additionally,31 biological processes were obtained by Gene Ontology enrichment,mainly related to lipopolysaccharide response and cytokine-mediated signal pathways,and 71 biological processes were obtained by Kyoto Encyclopedia of Genes and Genomes enrichment,mainly related to pulmonary tuberculosis,hepatitis B,and mitogen-activated protein kinase signal pathways.Conclusion:Shengmai decoction has multicomponent,multitarget and multichannel characteristics,which can provide an important theoretical basis to treat patients with severe COVID-19.展开更多
目的:研究黄芪生脉饮联合西医综合治疗小儿反复呼吸道感染的(RRTI)效果及免疫状况并进行分析。方法:选取2012年3月—2015年4月期间,医院收治的120例RRTI患者,采用随机数表法,将120例患者平均分为研究组和对照组,每个组各60例。发作期针...目的:研究黄芪生脉饮联合西医综合治疗小儿反复呼吸道感染的(RRTI)效果及免疫状况并进行分析。方法:选取2012年3月—2015年4月期间,医院收治的120例RRTI患者,采用随机数表法,将120例患者平均分为研究组和对照组,每个组各60例。发作期针对两组患者均采取常规西医治疗,缓解期针对对照组采取转移因子口服液治疗,10 m L/次,每天1次,口服;研究组患者采取黄芪生脉饮治疗,10 m L/次,2次/d,口服。两组患者治疗疗程都为8周,并且对所有患者行6个月的随访。观察记录患者的肺脾气虚证积分,检测治疗前后患者的T细胞亚群以及免疫球蛋白。结果:经治疗后研究组的总有效率高达98.33%,明显的高于对照组的有效率68.33%,并且差异具有统计学意义(χ~2=19.440 0,P=0.000 0);研究组患者治疗后IgG与IgA明显高于对照组,且差异具有统计学意义(P<0.05);研究组患者CD_3^+、CD_4^+、CD_8^+以及CD_4^+/CD_8^+改善程度明显地优于对照组,差异具有统计学意义(P<0.05);研究组患者治疗后各症状积分与肺脾气虚证总积分都显著低于对照组,差异具有统计学意义(P<0.05)。结论:发作期两组患者均采取常规西药治疗,缓解期采取黄芪生脉饮治疗,可显著地改善患儿体质,提高治疗有效率,减轻患儿的临床症状,减少痛疼,值得在临床上推广应用。展开更多
基金the Ph.D.Start-up Fund of Guangdong Medical University(No.B2019016)the Administration of Traditional Chinese Medicine of Guangdong Province(No.20201180)+4 种基金the Science and Technology Special Project of Zhanjiang(No.2019A01009)the Natural Science Foundation of Guangdong Province(No.2016B030309002)the Basic and Applied Basic Research Program of Guangdong Province(No.2019A1515110201)the Educational Commission of Guangdong Province(No.4SG20138G)the Fund of Southern Marine Science and Engineering Guangdong Laboratory(Zhanjiang)(No.ZJW-2019-007).
文摘Background:Studies have shown that,Shengmai injection(Shengmai decoction)which has been included in the diagnosis and treatment of coronavirus disease 2019(COVID-19),is effective in the early treatment of patients with severe COVID-19.However,the mechanism of its intervention in severe stage of COVID-19 at molecular level is still unclear.Therefore,it is necessary to further explore the mechanism of Shengmai decoction in the treatment of patients with severe COVID-19 based on network pharmacology.Methods:The Traditional Chinese Medicine Systems Pharmacology,BATMAN,UniProt databases and the published literatures which contain the reported compounds that have therapeutic effects on COVID-19 were used to screen out the active ingredients and targets of Shengmai decoction,and the“drug-active compound-target”network was constructed.The GeneCards database was used to screen out the targets of COVID-19.The protein-protein interaction network map was constructed by mapping two genes,and the network of active ingredients,targets and disease was constructed using Cytoscape software.Thereafter,Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of the key targets were performed using the Metascape Site Maintenance website and David databases.The Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes pathway enrichment of the mapping targets were analyzed.Results:The active component-target network contained 73 main compounds and 457 targets.The first five main active components(hydroquinone,guanosine,ophiopogon C,ophiopogon B,ophiopogon D)were obtained by topological analysis of 33 common targets.Using the Matthews correlation coefficient algorithm,the key targets included albumin,tumor necrosis factor,and cyclic adenosine response element binding.Compounds in Shengmai decoction were found to have good binding effect and strong interaction with caspase-8,caspase-3,apoptosis regulator Bcl-2,tumor necrosis factor,C-C motif chemokine 3,to inhibit the inflammatory response and improve lung injury.Additionally,31 biological processes were obtained by Gene Ontology enrichment,mainly related to lipopolysaccharide response and cytokine-mediated signal pathways,and 71 biological processes were obtained by Kyoto Encyclopedia of Genes and Genomes enrichment,mainly related to pulmonary tuberculosis,hepatitis B,and mitogen-activated protein kinase signal pathways.Conclusion:Shengmai decoction has multicomponent,multitarget and multichannel characteristics,which can provide an important theoretical basis to treat patients with severe COVID-19.
文摘目的:研究黄芪生脉饮联合西医综合治疗小儿反复呼吸道感染的(RRTI)效果及免疫状况并进行分析。方法:选取2012年3月—2015年4月期间,医院收治的120例RRTI患者,采用随机数表法,将120例患者平均分为研究组和对照组,每个组各60例。发作期针对两组患者均采取常规西医治疗,缓解期针对对照组采取转移因子口服液治疗,10 m L/次,每天1次,口服;研究组患者采取黄芪生脉饮治疗,10 m L/次,2次/d,口服。两组患者治疗疗程都为8周,并且对所有患者行6个月的随访。观察记录患者的肺脾气虚证积分,检测治疗前后患者的T细胞亚群以及免疫球蛋白。结果:经治疗后研究组的总有效率高达98.33%,明显的高于对照组的有效率68.33%,并且差异具有统计学意义(χ~2=19.440 0,P=0.000 0);研究组患者治疗后IgG与IgA明显高于对照组,且差异具有统计学意义(P<0.05);研究组患者CD_3^+、CD_4^+、CD_8^+以及CD_4^+/CD_8^+改善程度明显地优于对照组,差异具有统计学意义(P<0.05);研究组患者治疗后各症状积分与肺脾气虚证总积分都显著低于对照组,差异具有统计学意义(P<0.05)。结论:发作期两组患者均采取常规西药治疗,缓解期采取黄芪生脉饮治疗,可显著地改善患儿体质,提高治疗有效率,减轻患儿的临床症状,减少痛疼,值得在临床上推广应用。
